A Phase 4 interventional study of Ferric derisomaltose and Ferrous succinate in Perioperative Anemia, Surgery and Spinal Deformity, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-13.
Sponsored by Peking Union Medical College Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing iron isomaltoside 1000 in Anemia — 11 open to participants now, 11 under way, 3 of them phase 3. iron isomaltoside 1000 · Anemia.
Among the 29 studies testing iron isomaltoside 1000 in Anemia, this one is the 13th largest by planned enrollment, is one of 5 that started in 2023, is one of 13 in phase 4, reaches primary completion later than 1 of the 10 other live ones, and was the 21st registered.
1,812 studies on the registry are indexed under Anemia; 212 are open to participants now.
Browse Anemia studies →11 of the 29 studies testing iron isomaltoside 1000 in Anemia are open now, in 6 countries. Recruiting first, the newest first:
Hull University Teaching Hospitals NHS Trust · Sites in United Kingdom
Ages 18+
Soren Overgaard · Sites in Denmark
Ages 65+
AHS Cancer Control Alberta · Sites in Canada
Ages 18+ · Women only
China-Japan Friendship Hospital · Sites in China
Ages 18–65
Children's Hospital Los Angeles · Sites in United States
Ages 16–60 · Women only · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 117 Anemia studies recruiting now, 66 (56%) set no upper age limit and 33 (28%) stop at 75 or younger; 32 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is close to the median of 117 across 1,338 interventional studies indexed under Anemia.
Median enrollment 120 across the 29 interventional studies. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 29 have an industry lead sponsor. The 10 most frequent:
Peking Union Medical College Hospital is the lead sponsor of 1,158 studies on the registry; 477 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Peking Union Medical College Hospital has 4 studies filed under Anemia — fewer than ten, so there is no comparison to draw.
4 of the studies testing iron isomaltoside 1000 in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06884280Phase 3Hull University Teaching Hospitals NHS TrustComparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study | 2027-10 |
| NCT07236788China-Japan Friendship HospitalStudy on Supplement of Intravenous Ferric Derisomaltose to Prevent Anemia and Improve the Quality of Life in Obese Patients With Iron Deficiency. | 2026-12-30 |
| NCT06830941Xie Jingyuan, MDIron Isomaltoside for the Treatment of Anemia in Peritoneal Dialysis Patients | 2027-02-09 |
| NCT06898814Soren OvergaardThe Effects of Intravenous Iron on Mobility in Elderly Patients Following Hip Fracture Surgery | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 29 studies testing iron isomaltoside 1000 in Anemia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The prognosis of patients undergoing spinal deformity surgery is often compromised by perioperative anemia due to iron deficiency. The aim of this randomized, controlled trial was to evaluate whether postoperative ferric derisomaltose intravenous injection may improve anemia and prognosis in patients undergoing spinal deformity surgery comparing with oral iron. Participants will be randomly assigned to the treatment group (intravenous ferric derisomaltose) and the control group (oral iron). Changes in hemoglobin concentration, percentage of anemia correction, changes in iron indicators, patient quality of life, and incidence of adverse events will be analyzed to evaluate the efficacy and safety of iron isomaltoside infusion.
Iron deficiency is a common cause of perioperative anemia in patients undergoing spinal deformity surgery. Anemia may lead to increased postoperative complications and mortalities, prolonged hospital stays, deteriorated physical function, and severely affect the quality of life.
Oral iron has been widely recommended to treat perioperative anemia. However, the pro-inflammatory cytokines (such as IL-6 (Interleukin-6), TNF-a (Tumor necrosis factor-α)) produced by the inflammatory state after surgery can lead to an increase in hepcidin, which greatly affects the absorption of oral iron. Compared to oral iron, intravenous iron can circumvent the effects of decreased iron absorption in the gastrointestinal tract due to the postoperative inflammatory state and achieve faster and more effective iron supplementation. At present, intravenous iron supplements are mainly second-generation products, including iron sucrose and ferric gluconate. However, the unstable molecular structure of second-generation iron supplements may cause oxidative stress, which limits its administration in large doses.
Compared with traditional intravenous iron, the third-generation iron preparations allow more iron (1000 mg (milligram) or more, no more than 20 mg/kg (kilogram)) to be infused within a short period of time (15-60 minutes), improving patient compliance, reducing costs and complications caused by multiple infusions, and is promising to improve anemia more rapidly. Ferric derisomaltose, as the only third-generation iron currently available in China market, has showed its value in treating anemia in joint replacement surgeries. However, the effectiveness of postoperative intravenous ferric derisomaltose in spinal deformity surgery remains uncertain. Therefore, we designed this prospective randomized trial to evaluate whether intravenous ferric derisomaltose may improve anemia and prognosis in patients undergoing spinal deformity surgery compared with oral iron.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
70 g/L ≤ ≤ 110 g/L at POD1, or Hb at POD1 showed a decrease of
≥20 g/L compared with baseline
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Iron to be administered as intravenous ferric derisomaltose: Where Hb (hemoglobin) ≥100 g/L, dosage according to body weight is as follows: Body weight \<50 kg: 500mg; Body weight 50 to \<70 kg: 1000 mg; Body weight ≥70 kg: 1500 mg. Where Hb \<100 g/L, dosage according to body weight is as follows: Body weight \<50 kg: 500mg; Body weight 50 to \<70 kg: 1500mg; Body weight ≥70 kg: 2000 mg. The maximial dose should not exceed 20mg/kg body weight, rounded off to the nearest 100mg
Drug: Ferric derisomaltose
Iron to be administered as oral ferrous succinate: 1 tablet (100 mg) tid (three times daily), starting on the first postoperative day and continuing for 4 weeks.
Drug: Ferrous succinate
Single intravenous dose ferric derisomaltose
Also known as: MONOFER®
Daily oral dose of 100 mg iron (ferrous succinate) tid postoperatively
Change in hemoglobin concentration
Change in hemoglobin concentrations from POD(postoperative day)1 to POD14
Time frame: At 14 days
Change in hemoglobin concentration
Change in hemoglobin concentrations from POD1 to POD5
Time frame: At 5 days
Change in hemoglobin concentration
Change in hemoglobin concentrations from POD1 to POD35
Time frame: At 35 days
Correction of anemia
The percentage of effective correction of anemia (elevation of Hb \>20g/L or Hb ≥120g/L) at POD5
Time frame: At 5 days
Correction of anemia
The percentage of effective correction of anemia (elevation of Hb \>20g/L or Hb ≥120g/L) at POD14
Time frame: At 14 days
Correction of anemia
The percentage of effective correction of anemia (elevation of Hb \>20g/L or Hb ≥120g/L) at POD35
Time frame: At 35 days
Change in serum iron
Change in serum iron from POD1 to POD5
Time frame: At 5 days
Change in serum iron
Change in serum iron from POD1 to POD14
Time frame: At 14 days
Change in serum iron
Change in serum iron from POD1 to POD35
Time frame: At 35 days
Change in ferritin
Change in ferritin from POD1 to POD5
Time frame: At 5 days
Change in ferritin
Change in ferritin from POD1 to POD14
Time frame: At 14 days
Change in ferritin
Change in ferritin from POD1 to POD35
Time frame: At 35 days
Change in transferrin saturation
Change in transferrin saturation from POD1 to POD5
Time frame: At 5 days
Change in transferrin saturation
Change in transferrin saturation from POD1 to POD14
Time frame: At 14 days
Change in transferrin saturation
Change in transferrin saturation from POD1 to POD35
Time frame: At 35 days
Change in soluble transferrin receptor
Change in soluble transferrin receptor from POD1 to POD5
Time frame: At 5 days
Change in soluble transferrin receptor
Change in soluble transferrin receptor from POD1 to POD14
Time frame: At 14 days
Change in soluble transferrin receptor
Change in soluble transferrin receptor from POD1 to POD35
Time frame: At 35 days
EQ-5D
Quality of life measured by EQ-5D (European Quality of Life-5 Dimensions) at POD5
Time frame: At 5 days
EQ-5D
Quality of life measured by EQ-5D at POD14
Time frame: At 14 days
EQ-5D
Quality of life measured by EQ-5D at POD35
Time frame: At 35 days
Fatigue score
Fatigue measured FACIT-F (The Functional Assessment of Chronic Illness Therapy-Fatigue) questionnaire at POD5
Time frame: At 5 days
Fatigue score
Fatigue measured FACIT-F questionnaire at POD14
Time frame: At 14 days
Fatigue score
Fatigue measured FACIT-F questionnaire at POD35
Time frame: At 35 days
Barthel Index
Independence in daily activities measured by the Barthel questionnaire at POD 5
Time frame: At 5 days
Barthel Index
Independence in daily activities measured by the Barthel questionnaire at POD 14
Time frame: At 14 days
Barthel Index
Independence in daily activities measured by the Barthel questionnaire at POD 35
Time frame: At 35 days
Length of hospital stay
Hospitalized days
Time frame: At 3 months
Adverse events
Incidence of adverse events
Time frame: At 3 months
Infection
Incidence of postoperative infection
Time frame: At 3 months
Plan to share: Yes — Coded data is anticipated to be shared with potential collaborators.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Anticipated that data from the study will become available within 5 years after publication of main data.
Access criteria: Data would only be shared with IRB approved collaborators.
Started Aug 2023 (actual). Primary completion is estimated for Dec 2025, 28 months after the start.
Of 60 non-industry phase 4 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 48. This study's planned 28 months is above that.
Counting every sponsor, half of 74 studies reached it within 25 months; a quarter within 17 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iron isomaltoside 1000
Peking Union Medical College Hospital →